Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (RA-BioStop)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01602302 |
Recruitment Status :
Terminated
(low recruitment)
First Posted : May 18, 2012
Last Update Posted : December 1, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rheumatoid Arthritis | Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) | Phase 4 |
Rheumatoid arthritis (RA) is the most common inflammatory joint disease. It is usually treated with synthetic and biologic disease modifying antirheumatic drugs (DMARDs). Up to 35% of patients can achieve clinical remission by the combination these therapies; however, there is considerable uncertainty regarding the management of patients once this clinical state is achieved. The discontinuation of biological agents in patients with persistent clinical remission may be beneficial for the patients and the health care system reducing the risks of long term adverse events and saving costs, respectively. Up to 60% of patients were reported to flare after cessation of anti-tumor necrosis factor alpha (TNF alpha) therapy despite continuation of synthetic DMARDs and up to now there exist no validated biomarkers that predict which patients will suffer a flare and which patients will remain in remission.
Sonography is more and more used as a biomarker in RA. Subclinical inflammation was previously associated with an increased risk for short term clinical relapse and structural deterioration.
The hypothesis of this prospective study is that ultrasound verified subclinical inflammation at the time of bDMARD withdrawal predicts a disease flare at week 16. The investigators plan to recruit RA-patients with persistent clinical remission according to SDAI and no current corticosteroid therapy. At baseline, bDMARD is stopped, synthetic DMARDs are continued. Patients undergo 9 study visits within 52 weeks. Ultrasound examinations of 14 joints as well as clinical and laboratory assessments with calculation of SDAI scores are performed at each visit. Patients are considered to have a disease flare if disease status changes from remission to active disease according to clinical scores. Patients with a flare of the disease are excluded from the active phase of the study and are treated according to current guidelines.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis |
Study Start Date : | June 2012 |
Actual Primary Completion Date : | November 19, 2020 |
Actual Study Completion Date : | November 19, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: single arm ( bDMARD withdrawal )
single arm (bDMARD withdrawal)
|
Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)
bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
Other Names:
|
- PD-signals predict relapse at week 16 [ Time Frame: 16 weeks ]Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 16.
- PD-signals predict relapse at week 24 [ Time Frame: 24 weeks ]Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 24
- PD-signals predict relapse at week 52 [ Time Frame: 52 weeks ]Active inflammation at the time of bDMARD withdrawal indicated by the presence of a PD-score ≥1 in at least one joint out of a sonographic 14-joint count predicts relapse rate at week 52
- PD-scores at time of relapse [ Time Frame: 24 weeks ]RA-patients have higher PD-scores at time of a clinical flare compared to patients with maintained clinical remission
- Increment of PD-scores precede flare [ Time Frame: 52 weeks ]An increment of PD-scores at follow-up compared to baseline visits precedes a clinical flare
- PD scores better predict a relapse than residual swollen joints [ Time Frame: 16, 24, 52 weeks ]PD scores better predict a relapse at week 16, 24 and 52 than the presence of residual swollen joints
- PD score at baseline correlates with relapse risk [ Time Frame: 52 weeks ]The higher the PD score at baseline, the more likely is a relapse at weeks 16, 24 and/or 52
- 7. Patients converting from a rheumatoid factor (RF) positive to a RF negative status are less likely to experience a relapse at weeks 16, 24 and 52 than patients remaining seropositive [ Time Frame: 16, 24, 52 weeks ]7. Patients converting from a rheumatoid factor (RF) positive to a RF negative status are less likely to experience a relapse at weeks 16, 24 and 52 than patients remaining seropositive
- 8. Blood biomarkers predict the time to flare after bDMARD withdrawal8. Blood biomarkers predict the time to flare after bDMARD withdrawal
- 9. Blood biomarkers predict the time to re-achieve remission after flare and re-induction of bDMARD treatment9. Blood biomarkers predict the time to re-achieve remission after flare and re-induction of bDMARD treatment
- PD-scores and blood biomarkers at baseline predict radiographic progression at week 52 [ Time Frame: 52 ]PD-scores and blood biomarkers at baseline predict radiographic progression at week 52

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female patient ≥18 years and <90 years of age
- Classification of RA according to the ACR/EULAR 2010 criteria
- Persistent clinical remission as defined by the ACR/EULAR remission criteria for at least 6 months (documented at ≥2 visits)
- Written informed consent
- Current treatment with a single csDMARD or a combination of csDMARDs plus a stable dose and administration interval (for the last 6 months) of a TNF-alpha inhibitor
- No current systemic corticosteroid treatment (stopped for at least 4 weeks), no corticosteroid injection within 4 weeks
- Stable dose of NSAIDs for at least 1 week
Exclusion Criteria:
- • Current treatment with any investigational drug
- Current administration interval of the anti-TNF-alpha agent of >11 weeks
- Complete destruction of any joint to be investigated by sonography
- Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA- manifestation with the exception of rheumatoid nodules
- Initial arthritis manifestations before the age of 17 years
- Planned surgery within the study period or history of surgery of any of the joints to be investigated clinically or by sonography
- Current severe medical illness requiring hospitalization
- Active infection or active malignancy at screening or infection during the past 4 weeks requiring (even temporary) discontinuation of the anti-TNF-alpha agent
- Pregnancy or lactation
- Inability of the patient to follow the protocol
- Current treatment with Rituximab (MabThera®)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01602302
Austria | |
Medical University Graz | |
Graz, Austria, 8036 |
Principal Investigator: | Christian Dejaco, MD, PhD | Medical University of Graz |
Responsible Party: | Dejaco Christian, MD, PD, Dr., Medical University of Graz |
ClinicalTrials.gov Identifier: | NCT01602302 |
Other Study ID Numbers: |
2011-5; V2 2011-005204-15 ( EudraCT Number ) |
First Posted: | May 18, 2012 Key Record Dates |
Last Update Posted: | December 1, 2020 |
Last Verified: | November 2020 |
rheumatoid arthritis ultrasound remission biological DMARD |
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Adalimumab Etanercept Golimumab Abatacept Infliximab Certolizumab Pegol Anti-Inflammatory Agents |
Antirheumatic Agents Dermatologic Agents Gastrointestinal Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Tumor Necrosis Factor Inhibitors |